{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"MRD GATE RCC","nct_id":"NCT06005818","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mrd-gate-rcc-nct06005818. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MRD GATE RCC","arms":[{"description":null,"label":"Arm 1: MRD negative patients","type":"NO_INTERVENTION"},{"description":"Patients are treated with Pembrolizumab 400 mg IV q 6 weeks for a total of 1 year","label":"Arm 2 MRD positive patients","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-09","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab injection","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-21","lead_sponsor":"University of Alabama at Birmingham","official_title":"Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease Free Survival (DFS) by Investigator's assessment as defined by RECIST 1.1","timeFrame":"1 year from surgery"}],"references":[],"start_date":{"date":"2024-01-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)","url":"https://clinicaltrials.gov/study/NCT06005818"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mrd-gate-rcc-nct06005818"}